Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.
作者信息
Trave Ilaria, Salvi Ilaria, Bagnasco Diego, Parodi Aurora, Cozzani Emanuele
机构信息
Section of Dermatology - Department of Health Sciences, University of Genoa, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy.
Section of Respiratory Diseases and Allergology - Department of Internal Medicine (DIMI), University of Genoa, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy.
出版信息
Acta Derm Venereol. 2024 Sep 19;104:adv40800. doi: 10.2340/actadv.v104.40800.
Abstract
摘要
相似文献
1
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.特应性皮炎和哮喘患者发生嗜酸性粒细胞增多症时，曲罗芦单抗作为度普利尤单抗的替代药物：一例报告
Acta Derm Venereol. 2024 Sep 19;104:adv40800. doi: 10.2340/actadv.v104.40800.
2
Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient.一位特应性皮炎患者在使用度普利尤单抗后出现葡萄膜炎和嗜酸性粒细胞增多。
J Dermatolog Treat. 2023 Dec;34(1):2229466. doi: 10.1080/09546634.2023.2229466.
3
Systemic Biologic Management of Atopic Dermatitis.特应性皮炎的全身性生物治疗管理。
Adv Exp Med Biol. 2024;1447:139-149. doi: 10.1007/978-3-031-54513-9_13.
4
Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.接受度普利尤单抗治疗的中度至重度特应性皮炎患者中与度普利尤单抗相关的嗜酸性粒细胞增多症。
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e394-e396. doi: 10.1111/jdv.17177. Epub 2021 Mar 5.
5
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.青少年特应性皮炎或哮喘患者接受度普利尤单抗临床试验中的结膜炎。
Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1.
6
Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.2型炎症：度普利尤单抗成功治疗特应性皮炎、哮喘和高嗜酸性粒细胞增多症。
J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):261-263. doi: 10.18176/jiaci.0614. Epub 2020 Jul 30.
7
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
8
Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP.度普利尤单抗治疗下的高嗜酸性粒细胞增多症伴全身表现以及哮喘和慢性鼻-鼻窦炎伴鼻息肉患者使用贝那利珠单抗和度普利尤单抗联合治疗的可能性
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4477-4479. doi: 10.1016/j.jaip.2021.07.049. Epub 2021 Aug 9.
9
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series.患有眼表疾病的特应性皮炎患者从度普利尤单抗转换为曲罗芦单抗：初步病例系列
Clin Exp Allergy. 2023 May;53(5):586-589. doi: 10.1111/cea.14305. Epub 2023 Mar 16.
10
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.湿疹面积和严重程度指数（EASI）与改良湿疹面积和严重程度指数（p-EASI）：使用血清生物标志物组合预测接受度普利尤单抗治疗的特应性皮炎患者的疾病严重程度
Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.
本文引用的文献
1
Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis.度普利尤单抗与嗜酸性粒细胞性肺炎的潜在风险：病例报告、文献回顾和 FAERS 数据库分析。
Front Immunol. 2024 Jan 8;14:1277734. doi: 10.3389/fimmu.2023.1277734. eCollection 2023.
2
Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.生物制剂与嗜酸性粒细胞增多综合征：知识空白与争议
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2666-2671. doi: 10.1016/j.jaip.2023.07.026. Epub 2023 Jul 26.
3
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management.度匹鲁单抗引起的嗜酸性粒细胞增多症：文献复习及临床管理算法建议。
Expert Rev Respir Med. 2022 Jul;16(7):713-721. doi: 10.1080/17476348.2022.2090342. Epub 2022 Jun 23.
4
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.度普利尤单抗对哮喘、伴鼻息肉的慢性鼻-鼻窦炎、特应性皮炎或嗜酸性食管炎患者血液嗜酸性粒细胞计数的影响。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28.
5
Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.在使用度普利尤单抗治疗特应性皮炎期间，外周血嗜酸性粒细胞升高与基线合并症以及面部红斑性皮炎和眼表疾病的发生相关。
J Dermatolog Treat. 2022 Aug;33(5):2587-2592. doi: 10.1080/09546634.2022.2049588. Epub 2022 Mar 9.
6
Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma.在依赖皮质类固醇的重度哮喘患者中，从抗IL-5或抗IL-5R转换为度普利尤单抗治疗的并发症。
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2913-2915. doi: 10.1016/j.jaip.2021.02.042. Epub 2021 Mar 4.
7
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).特利鲁单抗治疗中重度特应性皮炎的两项 52 周、随机、双盲、多中心、安慰剂对照 III 期临床试验（ECZTRA1 和 ECZTRA2）结果。
Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30.
8
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab.1例使用度普利尤单抗治疗的慢性嗜酸性粒细胞性肺炎患者。
Ther Clin Risk Manag. 2019 Jul 10;15:869-875. doi: 10.2147/TCRM.S207402. eCollection 2019.
9
Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm.嗜酸性粒细胞增多性疾病：当前分类与诊断标准的评估，实用诊断算法的建议
Clin Transl Allergy. 2019 Jul 25;9:36. doi: 10.1186/s13601-019-0277-4. eCollection 2019.
10
Association of the blood eosinophil count with end-organ symptoms.血液嗜酸性粒细胞计数与终末器官症状的关联。
Ann Med Surg (Lond). 2019 Jul 9;45:11-18. doi: 10.1016/j.amsu.2019.06.015. eCollection 2019 Sep.
Zotero 插件